Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Administrative data

Description of key information

Oral:
Dog subchronic (13 weeks; gavage; RA to mixture of N,N-dimethyldecanamide and N,N-dimethyloctanamide) NOAEL (systemic) = 200mg/kg bw/d; NOEL (local) = 40mg/kg bw/d (Bayer 2000, J. Ruf)

Key value for chemical safety assessment

Repeated dose toxicity: via oral route - systemic effects

Endpoint conclusion
Endpoint conclusion:
adverse effect observed
Dose descriptor:
NOAEL
200 mg/kg bw/day
Study duration:
subchronic
Species:
dog

Additional information

Justification for grouping of substances and read-across

There are no reliable data available for repeated dose toxicity of N,N-Dimethyldodecan-amide (CAS 3007-53-2). In order to fulfil the standard information requirements set out in Annex VIII, 8.5, in accordance with Annex XI, 1.5, of Regulation (EC) No 1907/2006, read-across from structurally related substances was conducted.

In accordance with Article 13 (1) of Regulation (EC) No 1907/2006, "information on intrinsic properties of substances may be generated by means other than tests, provided that the conditions set out in Annex XI are met.” In particular for human toxicity, information shall be generated whenever possible by means other than vertebrate animal tests, which includes the use of information from structurally related substances (grouping or read-across).

Having regard to the general rules for grouping of substances and read-across approach laid down in Annex XI, Item 1.5, of Regulation (EC) No 1907/2006, whereby substances may be predicted as similar provided that their physicochemical, toxicological and ecotoxicological properties are likely to be similar or follow a regular pattern as a result of structural similarity, the substance listed below are selected as reference substances for hazard assessment.

 

 

Target Substance

Source Substance 1

Source Substance 2

Source Substance 3

 

N,N-Dimethyldodecan-amide

N,N-Dimethyldecan-amide

N,N-Dimethyloctanamide

Mixture of N,N-Dimethyloctanamide and N,N-Dimethyldecanamide

CAS

3007-53-2

14433-76-2

1118-92-9

67359-57-3

Repeated dose (oral)

(subchronic)

RA to 67359-57-3

RA to 67359-57-3

RA to 67359-57-3

OECD 409, beagle, 13 w, oral, NOAEL = 200mg/kg bw/d (Bayer 2000)

 

The above mentioned substances are considered to be similar on the basis of structural similarity resulting in similar properties and/or activities. The available endpoint information is used to predict the same endpoints for N,N-Dimethyldodecan-amide (CAS 3007-53-2). A detailed analogue approach justification is provided in the technical dossier (see IUCLID Section 13).

 

Mixture of dimethylamides (CAS 67359-57-3)

To assess the subchronic toxicity of a N,N-dimethylamide mixtures a subchronic dog study according to OECD Guideline No. 409 was performed (Bayer 2000, J. Ruf). Therefore Groups of 4 male and 4 female beagle dogs per dosage were treated once daily by gavage over a period of 13 weeks with following daily oral doses: 0 mg/kg bw; Group I : 40 mg/kg bw; Group II : 200 mg/kg bw; Group III : 1000 mg/kg bw From the second day of the study onwards, 1000 mg/kg were reduced to 800 mg/kg, and from the 4th day of the study onwards, 800 mg/kg were reduced to 500 mg/kg due to a markedly reduced health status of some group III-animals. The following result was given in the official report: “Tests of the reflexes, body temperatures, pulse rates, blood pressure, and heart rates showed no changes up to and including group III. The same holds true for the electrocardiograms . The nutritional state, feed intake, and body weight gain also yielded no adverse effects up to and including group III. Clinical observations evidenced repeated vomiting and salivation from group II upwards. Additional effects in group III consisted of uncoordinated movements, nasal discharge, lateral/prone position, and trembling. All these effects from group II upwards are considered to be due to treatment with the test compound. Animal no. B 915/group III had to be sacrificed on day 3 of the study showing lateral position, flat breathing, and bloody faeces before sacrificing, and animal no. B 944/group III died in week 7 of the study exhibiting lateral position, bloody nasal and oral discharge before death. Due to the lung findings observed in the histopathological investigations, these two events might be associated with an unintentional intratracheal application. Ophthalmoscopy showed a lens cataract in one animal of group III. This effect is seen to be treatment-related. Haematology and Differential blood counting showed no changes up to and including group III. Clinical chemistry evidenced a substance-related elevation of APh-values in group III. Increased N-Demethylase values from group II upwards and increased Cytochrome P450-values in group III are seen as treatment-related effects giving evidence for an increased metabolic activity in the liver. In this context the increased liver weights in males of group III are also considered to be treatment-related. Urinalyses showed no changes up to and including group III. Necropsy and histopathological examination did not reveal toxicologically relevant effects up to and including group III. Besides increased liver weights in males of group III (see above), no changes in organ weights were detected up to and including group III.” The author followed that based on the reported effects it can be concluded that 40 mg/kg test substance administered orally by gavages to beagle dogs daily over a period of 13 weeks were tolerated without adverse effects. 

In contrast to this conclusion the registrant assessed the effects observed as follow: The NOEL at 40 mg/kg bw/d (0.4%) reported is based on local effects caused by oral application of the test substance at irritating concentrations (≥2%). At 200 mg/kg bw/d clinical chemistry revealed only slightly increased N-DEM values in the absence of any other finding. The increase of this parameter is an indication for a minimal liver enzyme induction but not for an adverse effect. Therefore the NOAEL (systemic) is established at 200 mg/kg bw/d.

If valid information for the target substance is available this information is rated as highest in adequacy to judge about the repeated dose toxicity of N,N-dimethydodecanamide. As further the toxicity of the homologues increases with shorter carbon chain length towards C8, information from the next close homologue (N,N-dimethyldecanamide) is used if no information for the target is available or to underline less reliable target information. If no valid information from this close homologue (N,N-dimethyldecanamide) is available the Mixture of dimethylamides (CAS 67359-57-3) is used as information source followed by the pure N,N-dimethyloctanamid.

For repeated dose toxicity there are only studies with the mixture of dimethylamides (CAS 67359-57-3) available. The most relevant and reliable study concerning these endpoint is described above. Nevertheless there are also additional studies with rats (oral and inhalative, only range finder) conducted which results were rated less relevant and reliable as not contrast to the finding above. Therefore, these studies are not integrated.

Hence, taking reliability, adequacy and availability into account, the following information on repeated dose toxicity is used for assessment:

Dog subchronic (13 weeks; gavage; RA to mixture of N,N-dimethyldecanamide and N,N-dimethyloctanamide) NOAEL (systemic) = 200mg/kg bw/d; NOEL (local) = 40mg/kg bw/d (Bayer 2000, J. Ruf)

 

 

 

 


Justification for selection of repeated dose toxicity via oral route - systemic effects endpoint:
Most adequat reliable result, see discussion.

Justification for classification or non-classification

There are no data available leading to a classification of N,N-dimethyloctaneamide concerning its repeated oral, dermal or inhalation toxicity.

According to GHS (Regulation (EU) 1272/2008) the following criteria must be fullfilled:"3.9.2.1. Substances are classified as specific target organ toxicants...... 3.9.2.9.6. Thus classification in Category 1 is applicable, when significant toxic effects observed in a 90-day repeated dose study conducted in experimental animals are seen to occur at or below the guidance values (C).....

Category 1 classification: oral: C ≤ 10 mg/kg body weight/day

Category 2 classification: oral: 10 < C ≤ 100 mg/kg body weight/day

According to EU-criteria DSD (67/548/EEC) the following criteria must be fulfilled for the classification R48 Danger of serious damage to health by prolonged exposure “... Substances and preparations are classified at least as harmful when these effects are observed at levels of the order of (guide values): oral, rat ≤ 50 mg/kg body weight/day..."

As the lowest determined oral NOAEL (systemic) was higher than 100mg/kg body weight/day and lower values only led to local effect the substance has not to be classified derived for the oral repeated dose studies (Bayer 2000, J. Ruf).

Labelling repeated dose toxicity:

GHS: no classification

DSD: no classification